# NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

> **NCT05661201** · PHASE1 · RECRUITING · sponsor: **Georgetown University** · enrollment: 24 (estimated)

## Conditions studied

- Solid Tumor
- KRAS Mutation-Related Tumors

## Interventions

- **DRUG:** NEROFE
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT05661201
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-12
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05661201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05661201, "NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05661201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*